Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Allergan, Richter’s bipolar depression drug succeeds in key trial

Written by: | no-reply@reuters.com | Dated: Monday, December 18th, 2017

 

(Reuters) – Allergan Plc and Hungary’s Gedeon Richter Plc said on Monday their drug to treat severe bipolar depression in adults met the main goal of a late-stage study, bringing the them closer to getting another approval for the drug.

The drug, cariprazine, sold under the brand name Vraylar, is already approved to treat manic or mixed episodes of bipolar disorder and schizophrenia in adults.

The late-stage trial was testing two doses of cariprazine – 1.5 mg and 3 mg – in adults with major depressive episodes associated with bipolar disorder versus a placebo.

Bipolar disorder is characterized by dramatic shifts in mood, energy and activity levels that range from depressive lows to manic highs. It affects more than 5.7 million adults each year in the United States, according to the National Institute of Mental Health.

The companies said on Monday that both doses of the drug showed a statistically significant improvement in the severity of depressive episodes, as measured on the Montgomery-Asberg Depression Rating Scale (MADRS).

MADRS measures sadness, tension, suicidal thoughts and reduction of sleep and appetite in patients.

The companies said they would file an application to the U.S. Food and Drug Administration to get an additional approval for the drug in the second half of 2018.

Allergan’s shares were marginally up in light premarket trading.

 

Reporting by Divya Grover in Bengaluru; Editing by Martina D’Couto

 

Reuters source:

https://www.reuters.com/article/us-allergan-study/allergan-richters-bipolar-depression-drug-succeeds-in-key-trial-idUSKBN1EC1NA

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation